XML 61 R51.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Commitments and Contingencies - Tradipitant - Additional Information (Details) - Tradipitant - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | 144 Months Ended
--- | --- | --- | ---
Mar. 31, 2024 | Dec. 31, 2023 | Mar. 31, 2024
Commitments and Contingencies [Line Items] |  |  |
Future percentage of royalty payments based net sales | low double digits |  |
Development and milestone obligations paid to third party |  |  | $ 5.0
Pre-NDA Approval Milestones |  |  |
Commitments and Contingencies [Line Items] |  |  |
Possible future milestone payment |  | $ 2.0 |
Regulatory Approval Milestone | U.S. |  |  |
Commitments and Contingencies [Line Items] |  |  |
Possible future milestone payment | $ 10.0 |  |
Regulatory Approval Milestone | E.U. |  |  |
Commitments and Contingencies [Line Items] |  |  |
Possible future milestone payment | 5.0 |  |
Sales Milestone |  |  |
Commitments and Contingencies [Line Items] |  |  |
Possible future milestone payment | $ 80.0 |  |

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | vnda_CommitmentsAndContingenciesLineItems
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development And Milestone Obligations Paid To Third Party + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestoneObligationsPaidToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Total amount potentially due to third party under license agreement based on achievement of pre-new drug application approval milestones. + References No definition available. + Details
Name: | vnda_DevelopmentAndMilestonePaymentsPotentiallyDueToThirdParty
Namespace Prefix: | vnda_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Future Percentage Of Royalty Payments Based On Net Sales. + References No definition available. + Details
Name: | vnda_FuturePercentageOfRoyaltyPaymentsBasedOnNetSales
Namespace Prefix: | vnda_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vnda_TradipitantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_PreNDAApprovalMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_RegulatoryApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=vnda_SalesMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |